Contributions
Abstract: PB2483
Type: Publication Only
Background
Bone Marrow Transplantation (BMT) can be a life saving procedure in many conditions, however the lack of a HLA matched sibling or fully matched unrelated donor can be an impediment to proceed for a transplant. Haploidentical transplants using stem cells from familial donors who are only half matched to the recipients has become increasing popular in this context. This is especially relevant in the Indian subcontinent due to the lack of any large stem cell registries and costs associated with obtaining cells from overseas registries.
Aims
Here we report on our experience of haploidentical BMT in our tertiary BMT centre.
Methods
From February 2014 to September 2017, 20 haploidentical bone marrow transplantations were done in 19 patients. The age range was 5 months to 27 years with a median of 9 yrs. 14 male and 5 female patients underwent haploidentical BMT for indications ranging from malignant diseases such as relapsed AML or ALL, CML to benign diseases like Thalassemia Major, Chronic Granulomatous Disease and Aplastic Anaemia. The donors were parents or immediate siblings who were haploidentical to the recipients.
Results
3 of the 19 died due to transplant related toxicity. 1 child with aplastic anaemia had a first transplant from the father had a graft rejection and a second successful haploidentical BMT was done with the mother as the donor. All received T cell replete stem cells with Post Transplant Cyclophosphamide, MMF and a calcineurin inhibitor for GVHD prophylaxis. All but one (who received bone marrow stem cells) were transfused GCSF stimulated peripheral blood stem cells.
Conclusion
With a median follow up period of 8 months our data is still young, however, with an overall survival of 84%, haploidentical bone marrow transplant is a promising new option available for those who lack other appropriate donors.
Session topic: 23. Stem cell transplantation - Clinical
Keyword(s): Haploidentical stem cell transplantation
Abstract: PB2483
Type: Publication Only
Background
Bone Marrow Transplantation (BMT) can be a life saving procedure in many conditions, however the lack of a HLA matched sibling or fully matched unrelated donor can be an impediment to proceed for a transplant. Haploidentical transplants using stem cells from familial donors who are only half matched to the recipients has become increasing popular in this context. This is especially relevant in the Indian subcontinent due to the lack of any large stem cell registries and costs associated with obtaining cells from overseas registries.
Aims
Here we report on our experience of haploidentical BMT in our tertiary BMT centre.
Methods
From February 2014 to September 2017, 20 haploidentical bone marrow transplantations were done in 19 patients. The age range was 5 months to 27 years with a median of 9 yrs. 14 male and 5 female patients underwent haploidentical BMT for indications ranging from malignant diseases such as relapsed AML or ALL, CML to benign diseases like Thalassemia Major, Chronic Granulomatous Disease and Aplastic Anaemia. The donors were parents or immediate siblings who were haploidentical to the recipients.
Results
3 of the 19 died due to transplant related toxicity. 1 child with aplastic anaemia had a first transplant from the father had a graft rejection and a second successful haploidentical BMT was done with the mother as the donor. All received T cell replete stem cells with Post Transplant Cyclophosphamide, MMF and a calcineurin inhibitor for GVHD prophylaxis. All but one (who received bone marrow stem cells) were transfused GCSF stimulated peripheral blood stem cells.
Conclusion
With a median follow up period of 8 months our data is still young, however, with an overall survival of 84%, haploidentical bone marrow transplant is a promising new option available for those who lack other appropriate donors.
Session topic: 23. Stem cell transplantation - Clinical
Keyword(s): Haploidentical stem cell transplantation